Axxam announced today that it has signed an agreement with the National Institutes of Health (NIH) to provide access to a selection of screening assays of special interest to the NIH Chemical Genomics Centre (NCGC) for use in the screening campaigns within the Molecular Libraries Roadmap Initiative.
The screening assays were developed and optimized at Axxam for ultra high-throughput screening (uHTS) applications using ultra sensitive signal detection methods. “We are very pleased to collaborate with the NIH Chemical Genomics Centre in support of their screening efforts,” stated Dr. Lia Scarabottolo, head of cell biology at Axxam. “We believe that our expertise in the uHTS sector, with a particular emphasis on cellbased assays and their use in large screening campaigns, could provide an important contribution to the future success of the Roadmap initiative at the NCGC.”
About the NCGC and the NIH Roadmap Initiative The NCGC is an ultrahigh-throughput screening and chemistry centre which discovers chemical probes of gene and cell functions across the genome using its quantitative HTS (qHTS) technology, and develops new paradigms for screening that enable chemical genomics and downstream drug development. Located within the National Human Genome Research Institute as part of the NIH Roadmap, all of the NCGC’s results are made freely available via PubChem (http://pubchem.ncbi.nlm.nih.gov). NIH Roadmap for Medical research is a series of far-reaching initiatives designed to transform the Nation’s medical research capabilities and speed the movement of scientific discoveries from the bench to the bedside. It provides a framework of the priorities the NIH must address in order to optimize its entire research portfolio and lays out a vision for a more efficient and productive system of medical research. Additional information about the NCGC can be found at http://www.ncgc.nih.gov, about the NIH Roadmap at http://nihroadmap.nih.gov , and about the NIH at http://www.nih.gov/.
About Axxam Axxam is a leading research-driven solution provider for the life sciences industries. Expert teams of Axxam scientists partner with pharmaceutical, biotechnology and agrochemical companies to provide comprehensive ‘from genes to leads’ activities. Platforms include target identification, assay development, high-throughput screening (HTS) and lead profiling utilizing the latest technologies. Axxam is continually developing innovative tools and technologies to improve assay performance such as Photina™, an outstanding and novel calcium-detecting photo protein, which allows superior results on all major flash luminescence readers. For more information, please visit www.axxam.com or contact
Suzanne Beveridge, Chief Corporate Communications Tel: +39 02 2105664 Email: suzanne.beveridge.sb@axxam.com Axxam San Raffaele Biomedical Science Park Via Olgettina 58 20132 Milan, Italy
